A. G. Saltykova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. G. Saltykova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay I. Briko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Roman V. Polibin
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Vladimir A. Korshunov
Sechenov University
2 shared publications - A. A. Pozdnyakov
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - A. V. Shamis
SBIH Vorohobov's City Clinical Hospital №67 MHD
1 shared publication - Alla Ya. Mindlina
Sechenov University
1 shared publication
Latest Publications
- Open Access
- 14 January 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (6) , 104-113
Evaluation of the Epidemiological Effectiveness of a Quadrivalent Inactivated Split Influenza Vaccine in the 2023–2024 flu season
Relevance. A distinctive feature of the influenza is the risk of severe complications, including cardiovascular (myocarditis or pericarditis) and nervous (encephalitis, meningoencephalitis and arachnoiditis) systems. Vaccination against influenza can significantly reduce the risk of disease, including complications and deaths.The aim of our study was to evaluate the epidemiological effectiveness of a quadrivalent inactivated split influenza vaccine in the 2023 –2024 season.Materials and methods. The study investigated the effectiveness of the tetravalent inactivated split vaccine Ultrix Quadri®. Vaccination data were collected in the regions of the Russian Federation as of January 1, 2024, in which a statistically significant amount of Ultrix Quadri® vaccine was used. The work was carried out using methods of variational statistics. The indicators of relative and attributive risks were evaluated, the Cochrane-Mantel-Hensel approach was applied, taking into account the assessment of heterogeneity of the results, and the effectiveness of the vaccine was evaluated.Results. The study showed that the risk of getting the flu among those vaccinated with Ultrix Quadri® vaccine was 122 (88-170) times lower than in those not vaccinated, which indicates the high epidemiological effectiveness of the vaccine. Cases of influenza among those vaccinated were observed in December 2023 - January 2024, that is, at the beginning of the epidemic season, during the period of the greatest rise in morbidity. At the same time, in absolute terms, their number was minimal. (414 cases out of 9.7 million vaccinated). From February to June 2024, the incidence of influenza among those vaccinated with the studied vaccine (with the exception of isolated cases) was not recorded.Conclusion. The conducted study demonstrated the high real epidemiological effectiveness of the Ultrix Quadri® vaccine during the epidemic season of influenza and ORI 2023/2024.
- 14 January 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (6) , 104-113
Open AccessEvaluation of the Epidemiological Effectiveness of a Quadrivalent Inactivated Split Influenza Vaccine in the 2023–2024 flu season
Relevance. A distinctive feature of the influenza is the risk of severe complications, including cardiovascular (myocarditis or pericarditis) and nervous (encephalitis, meningoencephalitis and arachnoiditis) systems. Vaccination against influenza can significantly reduce the risk of disease, including complications and deaths.The aim of our study was to evaluate the epidemiological effectiveness of a quadrivalent inactivated split influenza vaccine in the 2023 –2024 season.Materials and methods. The study investigated the effectiveness of the tetravalent inactivated split vaccine Ultrix Quadri®. Vaccination data were collected in the regions of the Russian Federation as of January 1, 2024, in which a statistically significant amount of Ultrix Quadri® vaccine was used. The work was carried out using methods of variational statistics. The indicators of relative and attributive risks were evaluated, the Cochrane-Mantel-Hensel approach was applied, taking into account the assessment of heterogeneity of the results, and the effectiveness of the vaccine was evaluated.Results. The study showed that the risk of getting the flu among those vaccinated with Ultrix Quadri® vaccine was 122 (88-170) times lower than in those not vaccinated, which indicates the high epidemiological effectiveness of the vaccine. Cases of influenza among those vaccinated were observed in December 2023 - January 2024, that is, at the beginning of the epidemic season, during the period of the greatest rise in morbidity. At the same time, in absolute terms, their number was minimal. (414 cases out of 9.7 million vaccinated). From February to June 2024, the incidence of influenza among those vaccinated with the studied vaccine (with the exception of isolated cases) was not recorded.Conclusion. The conducted study demonstrated the high real epidemiological effectiveness of the Ultrix Quadri® vaccine during the epidemic season of influenza and ORI 2023/2024.
- Open Access
- 17 March 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (1) , 92-97
The Role of the Educational Programs in the Improving of Confidence in Vaccination against Pneumococcal Infection among Population
Роль образовательного компонента в формировании приверженности населения к вакцинации против пневмококковой инфекции
- 17 March 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (1) , 92-97
Open AccessThe Role of the Educational Programs in the Improving of Confidence in Vaccination against Pneumococcal Infection among Population
Роль образовательного компонента в формировании приверженности населения к вакцинации против пневмококковой инфекции